Simulations PlusSLP
SLP
0
Funds holding %
of 7,398 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
93% more call options, than puts
Call options by funds: $393K | Put options by funds: $204K
18% more repeat investments, than reductions
Existing positions increased: 59 | Existing positions reduced: 50
1.8% more ownership
Funds ownership: 77.27% [Q3] → 79.07% (+1.8%) [Q4]
3% less funds holding
Funds holding: 169 [Q3] → 164 (-5) [Q4]
10% less capital invested
Capital invested by funds: $495M [Q3] → $443M (-$51.8M) [Q4]
13% less first-time investments, than exits
New positions opened: 27 | Existing positions closed: 31
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$35
46%
upside
Avg. target
$36
51%
upside
High target
$37
55%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
Keybanc Brett Fishbin 24% 1-year accuracy 4 / 17 met price target | 55%upside $37 | Overweight Maintained | 24 Jan 2025 |
Keybanc Scott Schoenhaus 26% 1-year accuracy 8 / 31 met price target | 46%upside $35 | Overweight Maintained | 8 Jan 2025 |
Financial journalist opinion
Based on 4 articles about SLP published over the past 30 days
Positive
Zacks Investment Research
4 hours ago
Simulations Plus Gears Up for Q2 Earnings: What's in the Offing?
SLP's fiscal Q2 2025 performance is likely to have benefited from continued momentum across its Software and Services segments amid budget constraints.

Positive
Benzinga
6 days ago
Top 3 Health Care Stocks That Are Set To Fly This Month
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Neutral
Business Wire
1 week ago
Simulations Plus Announces Second Quarter Fiscal Year 2025 Earnings and Conference Call Date
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”, “SLP”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced that it will report second quarter fiscal 2025 financial results after the market close on Thursday, April 3, 2025. Management will host a conference call that same day at 5:00 p.m. Eastern Time to discu.

Neutral
Business Wire
3 weeks ago
Simulations Plus to Present at the KeyBanc Capital Markets Virtual Healthcare Investor Forum
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”, “SLP”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced that Shawn O'Connor, Chief Executive Officer, will be participating in a fireside chat at the KeyBanc Capital Markets Virtual Healthcare Investor Forum on Tuesday, March 18, 2025, at 2:15 p.m. Eastern Ti.

Neutral
Business Wire
1 month ago
Simulations Plus to Participate in Upcoming Healthcare Investor Conferences
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”, “SLP”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced that it will participate in two healthcare investor conferences in February. The Company is attending the BTIG 12th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference taking p.

Neutral
Business Wire
2 months ago
Simulations Plus and Enabling Technologies Consortium Announce Strategic Collaboration to Advance GastroPlus® Enhancements
RESEARCH TRIANGLE, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced that it has entered a new funded collaboration with the Enabling Technologies Consortium (ETC). This partnership is aimed at advancing in vitro-in vivo correlation (IVIVC) approaches for oral drug delivery and expanding the function.

Neutral
Business Wire
2 months ago
Simulations Plus Supported Development of Majority of FDA-Approved Drugs in 2024
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--SLP highlighted its impact on the pharma industry through support of the development of a majority of the drugs approved by the U.S. FDA in 2024.

Neutral
Business Wire
2 months ago
Simulations Plus Supported Development of Every FDA-Approved Drug in 2024
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--SLP highlighted its impact on the pharmaceutical industry through supporting the development of 100% of the drugs approved by the U.S. FDA in 2024.

Neutral
Zacks Investment Research
2 months ago
Simulations Plus' Q1 Earnings Lag Estimates, Revenues Surge Y/Y
SLP's fiscal first-quarter performance is driven by healthy revenue growth across its Software segment and contributions from the acquisition of Pro-ficiency.

Neutral
Seeking Alpha
2 months ago
Simulations Plus, Inc. (SLP) Q1 2025 Earnings Call Transcript
Simulations Plus, Inc. (NASDAQ:SLP ) Q1 2025 Earnings Conference Call January 7, 2025 5:00 PM ET Company Participants Lisa Fortuna - IR, Financial Profiles Shawn O'Connor - CEO Will Frederick - CFO & COO Conference Call Participants David Larsen - BTIG Francois Brisebois - Oppenheimer & Company Christine Rains - William Blair Scott Schoenhaus - KeyBanc Capital Markets Matt Hewitt - Craig-Hallum Jeff Garro - Stephens Operator Greetings, and welcome to the Simulations Plus First Quarter Fiscal 2025 Financial Results Conference Call. At this time, all participants are in a listen-only mode.

Charts implemented using Lightweight Charts™